Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 57.00
Bid: 54.00
Ask: 60.00
Change: 1.00 (1.79%)
Spread: 6.00 (11.111%)
Open: 56.00
High: 57.00
Low: 56.00
Prev. Close: 56.00
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker Option

21 Mar 2022 17:56

RNS Number : 5151F
MyCelx Technologies Corporation
21 March 2022
 

THIS ANNOUNCEMENT, (INCLUDING THE APPENDICES) AND THE TERMS AND CONDITIONS SET OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT") AND THE INFORMATION CONTAINED THEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, DISTRIBUTION OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO ANY US PERSONS OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

 

21 March 2022

MYCELX Technologies Corporation

("MYCELX" or the "Company")

Broker Option

 

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to announce that further to the announcement of the Proposed Placing and Subscription on 11 March 2022, the Broker Option has been exercised in respect of 155,000 new Common Shares (the "Broker Option Shares"), raising additional gross proceeds of $101,500 (c £77,500) for the Company.

The Broker Option Shares will be issued at a price of 50 pence per new Common Share (being the Issue Price) and on the same terms and conditions as the Placing, including the fact that they are to be issued into the new restricted line of Common Shares under the symbol MYXR. 

With the exercise of the Broker Option and the admission of the Placing and Subscription to trading on AIM, this results in a total gross fundraise of $2.31million (c.£1.77 million*) for the Company; comprising the Placing and Subscription raising c.$2.21 million (c.£1.69 million*) (before expenses), and the Broker Option raising $101,500 (c.£77,500*).

Admission and dealings

Application will be made to the London Stock Exchange for the 155,000 Broker Option Shares to be admitted to trading on AIM (the "Further Admission"). Admission of the Placing and Subscription became effective on 21 March 2022, the Broker Option Shares are expected to become effective and dealings commence at 8.00 a.m. on or around 25 March 2022.

The new Common Shares to be issued in connection with the Placing and Subscription and the Broker Option, when issued, rank pari passu with the existing Common Shares, including the right to receive future dividends.

Upon the Further Admission, the new Common Shares issued pursuant to the Broker Option will also trade in the Company's new restricted line of Common Shares under the symbol MYXR, and the new Common Shares, as represented by depositary interests ("Depository Interests"), will be held in the CREST system and will be segregated into a separate trading system within CREST identified with the marker "REG S" and USU624551235.

Total Voting Rights

Following the Further Admission, and as a result of the Broker Option being partially exercised, the total number of Common Shares in the Company with voting rights is expected to be 22,983,023.

Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Company's announcements dated 11 March 2022 regarding the Proposed Placing and Subscription unless otherwise stated.

 

*Exchange rate of GBP: USD 1.31

further information, please contact:

 

MYCELX Technologies Corporation

 

Connie Mixon, Chief Executive Officer

 

+1 770 534 3118

Kim Slayton, Chief Financial Officer

 

 

Canaccord Genuity Limited (NOMAD, Broker and Bookrunner)

Henry Fitzgerald-O'Connor

Gordon Hamilton

Sam Lucas (ECM)

+44 207 523 8000

 

 

Celicourt Communications (Financial PR)

 

Mark Antelme

+44 208 434 2643

Jimmy Lea

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURUASBRUWUOUAR
Date   Source Headline
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.